A prognostic stemness biomarker CCDC80 reveals acquired drug resistance and immune infiltration in colorectal cancer

Wei-Da Wang; Guo-Yan Wu; Kun-Hao Bai; Ling-Ling Shu; Pei-Dong Chi; Si-Yuan He; Xin Huang; Qian-Yi Zhang; Liang Li; Da-Wei Wang; Yu-Jun Dai

doi:10.1002/ctm2.225

A prognostic stemness biomarker CCDC80 reveals acquired drug resistance and immune infiltration in colorectal cancer

Clin Transl Med. 2020 Oct;10(6):e225. doi: 10.1002/ctm2.225.

Authors

Wei-Da Wang^{1

2

3}, Guo-Yan Wu⁴, Kun-Hao Bai^{1

3

5}, Ling-Ling Shu^{1

2

3}, Pei-Dong Chi^{1

2

3}, Si-Yuan He⁶, Xin Huang^{1

3}, Qian-Yi Zhang^{1

2

3}, Liang Li^{1

2

3}, Da-Wei Wang⁷, Yu-Jun Dai^{1

2

3}

Affiliations

¹ State Key Laboratory of Oncology in South China, Guangzhou, China.
² Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
³ Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
⁴ Department of Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
⁵ Department of Endoscopy, Sun Yat-sen University Cancer Center, Guangzhou, China.
⁶ The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, Texas, USA.
⁷ National Research Center for Translational Medicine, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

No abstract available

Publication types

Letter

Grants and funding

GCQN-2019-B17/Guangci Distinguished Young Scholars Training Program